Tin tức & Cập nhật

Chỉ hiển thị Multimedia
First-line, reduced-dose eribulin mesylate disappoints in older adults with metastatic breast cancer

First-line, reduced-dose eribulin mesylate disappoints in older adults with metastatic breast cancer

27 Sep 2022

Among older patients with metastatic breast cancer, first-line treatment with reduced-dose eribulin mesylate is reasonably safe but yields a low disease control rate, reports a recent phase II trial.

27 Sep 2022